AbbVie Inc (ABBV)

NYSE
Currency in USD
185.48
-5.38(-2.82%)
Closed·
After Hours
185.76+0.28(+0.15%)
·
ABBV Scorecard
Full Analysis
Has raised its dividend for 12 consecutive years
ABBV is included in our AI-picked strategies. See how they work
Fair Value
Day's Range
185.06190.61
52 wk Range
163.52218.66
Key Statistics
Edit
Prev. Close
190.86
Open
189.16
Day's Range
185.06-190.61
52 wk Range
163.52-218.66
Volume
4.6M
Average Volume (3m)
7.66M
1-Year Change
13.21%
Book Value / Share
0.8
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
ABBV Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
208.86
Upside
+12.61%
Members' Sentiments
Bearish
Bullish
ProTips
Net income is expected to grow this year

AbbVie Inc News & Analysis

Show more

AbbVie Inc Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta/Venclyxto to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic to treat neurologic diseases; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duopa and Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; and Qulipta for episodic and chronic migraine, as well as other neuroscience products. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Employees
55000

AbbVie Inc SWOT Analysis


Immunology Powerhouse
AbbVie's Skyrizi and Rinvoq drive growth, offsetting Humira's decline. Combined revenue projected to exceed $31 billion by 2027, showcasing strong market position.
Pipeline Potential
Explore AbbVie's robust pipeline, including emraclidine for schizophrenia. Strategic acquisitions and upcoming clinical trials promise to diversify revenue streams.
Analyst Optimism
Wall Street bullish on AbbVie's prospects. Price targets range from $195 to $240, with majority rating stock as Outperform or Overweight.
Navigating Challenges
Delve into AbbVie's strategies for managing biosimilar competition, pricing pressures, and market dynamics in aesthetics business to maintain industry leadership.
Read full SWOT analysis

AbbVie Inc Earnings Call Summary for Q1/2025

  • AbbVie beats Q1 expectations with adjusted EPS of $2.46 and revenue of $13.3B, exceeding forecasts by $550M
  • Full-year EPS guidance raised to $12.09-$12.29, with high single-digit revenue growth projected through 2029
  • Strong growth in SKYRIZI and RINVOQ sales offset HUMIRA declines; $10B investment planned for U.S. manufacturing
  • Stock up 0.19% post-announcement; analysts see potential upside with targets ranging from $173 to $250 per share
  • CEO highlights clear growth runway for next 8 years, expecting to exceed previous peak revenue post-HUMIRA LOE
Last Updated: 2025-04-25, 10:28 a/m
Read Full Transcript

Compare ABBV to Peers and Sector

Metrics to compare
ABBV
Peers
Sector
Relationship
P/E Ratio
78.9x−2.7x−0.5x
PEG Ratio
−2.640.040.00
Price/Book
230.8x2.6x2.6x
Price / LTM Sales
5.7x7.3x3.1x
Upside (Analyst Target)
8.7%52.7%48.6%
Fair Value Upside
Unlock35.0%8.9%Unlock

Analyst Ratings

16 Buy
12 Hold
0 Sell
Ratings:
28 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 208.86
(+12.61% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 2.35%
Dividend Yield
3.44%
Industry Median 1.73%
Annualized payout
6.56
Paid quarterly
5-Years Growth
+7.23%
Growth Streak

Earnings

Latest Release
Apr 25, 2025
EPS / Forecast
2.46 / 2.39
Revenue / Forecast
13.34B / 12.93B
EPS Revisions
Last 90 days

ABBV Income Statement

People Also Watch

308.84
UNH
+0.38%
102.87
FTNT
+0.90%
208.18
ORCL
-1.38%
67.09
CVS
-0.92%

FAQ

What Is the AbbVie (ABBV) Stock Price Today?

The AbbVie stock price today is 185.48

What Stock Exchange Does AbbVie Trade On?

AbbVie is listed and trades on the New York Stock Exchange stock exchange.

What Is the Stock Symbol for AbbVie?

The stock symbol for AbbVie is "ABBV."

Does AbbVie Pay Dividends? What’s The Current Dividend Yield?

The AbbVie dividend yield is 3.44%.

What Is the AbbVie Market Cap?

As of today, AbbVie market cap is 327.10B.

What Is AbbVie's Earnings Per Share (TTM)?

The AbbVie EPS (TTM) is 2.35.

When Is the Next AbbVie Earnings Date?

AbbVie will release its next earnings report on Jul 25, 2025.

From a Technical Analysis Perspective, Is ABBV a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has AbbVie Stock Split?

AbbVie has split 0 times.

How Many Employees Does AbbVie Have?

AbbVie has 55000 employees.

What is the current trading status of AbbVie (ABBV)?

As of Jun 18, 2025, AbbVie (ABBV) is trading at a price of 185.48, with a previous close of 190.86. The stock has fluctuated within a day range of 185.06 to 190.61, while its 52-week range spans from 163.52 to 218.66.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.